Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized double-blind Phase III trial of inhaled formoterol Turbuhaler in COPD
jRCT2080220626Phase 3
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca.
02
Drugs
formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080220626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220626.